natgillin/translations-raw huggingface dataset:
No teratogenic effects or effects on foetal development have been observed, but the available information on the effects of interferon beta-1a in the peri- and postnatal periods is limited.
Teratogenih učinkov in vpliva na razvoj fetusa ni bilo moč opaziti, a informacije, ki so na voljo o učinkih interferona beta-1a v perinatalnem in postnatalnem obdobju, so skope.
No teratogenic effects were observed in rabbits at >1,000 times human exposure.
Pri kuncih več kot 1.000-krat večja izpostavljenost kot za človeka ni bila povezana s teragotenimi učinki.
No teratological or embryo/foetal effects were observed in rabbits, although maternal toxicity was marked at 0.1 mg/kg due to decreased serum calcium levels.
Pri kuncih niso opazili teratogenih učinkov ali učinkov na zarodek ali plod, čeprav je bila toksičnost za mater pri odmerku 0,1 mg/kg znatna zaradi znižanih koncentracij kalcija v serumu .
No toxicities occurred notably more frequently among patients at least 65 years of age who received Abraxane.
Pri bolnikih, ki so bili stari vsaj 65 let in so jemali zdravilo Abraxane, niso opazili pogostejše toksičnosti.
No toxicity was observed when rhesus monkeys received intravenous doses of either up to 5 mg/kg basiliximab twice weekly for 4 weeks followed by an 8-week withdrawal period or 24 mg/kg basiliximab weekly for 39 weeks followed by a 13-week withdrawal period.
Ko so opicam rezus dvakrat tedensko dajali intravenske odmerke bodisi do 5 mg/kg telesne mase baziliksimaba 4 tedne zapored, čemur je sledilo 8-tedensko obdobje brez zdravila, bodisi 24 mg/kg telesne mase baziliksimaba 39 tednov, čemur je sledilo 13-tedensko obdobje brez zdravila, niso opazili toksičnosti.
No transfusion
Brez transfuzije
no treatment
brez zdravljenja
No treatment experience is available for this subpopulation of patients, and therefore the use of Pradaxa is not recommended in this population (see sections 4.4 and 5.2).
Za to podpopulacijo bolnikov z zdravljenjem ni izkušenj, zato uporabe zdravila Pradaxa za to skupino bolnikov ne priporočamo (glejte poglavji 4.4 in 5.2).
No treatment experience is available for this subpopulation of patients, and therefore the use of Pradaxa is not recommended in this population (see sections 4.4 and 5.2).
Za to podpopulacijo bolnikov z zdravljenjem ni izkušenj,zato uporabe zdravila Pradaxa za to skupino bolnikov ne priporočamo (glejte poglavji 4.4 in 5.2).
No treatment experience is available for this subpopulation of patients, and therefore the use of Pradaxa is not recommended in this population.
Z zdravljenjem te populacije bolnikov ni izkušenj zato uporabe zdravila Pradaxa za to skupino bolnikov ne priporočamo.
No treatment experience is available for this subpopulation of patients, and therefore the use of Pradaxa is not recommended in this population.
Za to podpopulacijo bolnikov z zdravljenjem ni izkušenj, zato uporabe zdravila Pradaxa za to skupino bolnikov ne priporočamo.
No treatment failure defined as positive HBV-DNA and HBsAg findings occurred during the entire observation period.
Ves čas opazovanja niso opazili neuspeha zdravljenja, opredeljenega kot pozitivne vrednosti HBV-DNA in HBsAg.
No treatment failures occurred during the 6- month study period.
V 6-mesečnem obdobju študije ni bilo nobenega primera neuspešnega zdravljenja.
No treatment requiring bleeding episodes have been detected in patients below 6 years during 8.7 years of cumulative follow-up, representing a total of 116 doses.
Pri bolnikih, mlajših od 6 let, med 8,7 leta trajajočim kumulativnim spremljanjem (to pomeni v celoti 116 odmerkov) niso zabeležili epizod krvavitev, ki bi zahtevale zdravljenje.
No treatment- related effects have been identified in reproductive tissues of either sex during repeat dose intravenous toxicity studies of up to four weeks in the rat and two weeks in monkeys.
Z zdravljenjem povezanih učinkov na reproduktivna tkiva katerega koli spola na osnovi študij intravenske toksičnosti pri ponavljajočih se odmerkih, ki so pri podganah trajale do štiri tedne in pri opicah do dva tedna, niso ugotovili.
No treatment-related pancreatitis was reported in the phase 3 pNET study.
V študiji 3. faze pri pNET niso poročali o nobenem primeru pankreatitisa, ki bi bil povezan z zdravljenjem.
No Trizivir dosage adjustment necessary, unless patient has renal impairment (See Section 4.2).
Prilagoditev odmerjanja zdravila Trizivir ni potrebna, razen če ima bolnik okvaro ledvic (glejte poglavje 4.2).
No tumourigenic potential of iloprost was observed in tumourigenicity studies in rats and mice.
V študijah kancerogenosti na podganah in miših niso dokazali kancerogenega potenciala iloprosta.
No unchanged drug was detected in urine so the impact of renal impairment on etravirine elimination is expected to be minimal.
V seču nespremenjenega zdravila niso odkrili, zato je pričakovati, da bo vpliv ledvične okvare na izločanje etravirina minimalen.
No unchanged mitotane has been found in bile or in urine, where o,p’-DDA predominates, together with several of its hydroxylated metabolites.
V žolču ali v urinu ne najdemo nespremenjenega mitotana, prevladuje pa o,p’-DDA skupaj z več svojimi hidroksiliranimi presnovki.
No unchanged parecoxib is detected in urine and only trace amounts in the faeces.
V seču ni nespremenjenega parekoksiba, v blatu pa se pojavlja le v sledeh.
No unchanged substance is eliminated.
V nespremenjeni obliki se ne izloča.
No undesirable effect has been observed after the administration of several doses except those mentioned in the “Adverse reactions” section.
Po vnosu večkratnih odmerkov cepiva niso opazili nobenih drugih neželenih učinkov razen tistih, navedenih v poglavju »Neželeni učinki«.
No undesirable effects of a murine anti-murine IL-1 beta antibody were seen in a complete set of reproductive and juvenile studies in mice.
V celotni vrsti študij vpliva na sposobnost razmnoževanja in razvoj mladičev na miših niso opažali nobenih neželenih učinkov glodalskih protiteles proti glodalskemu IL-1 beta.
No undesirable effects of a murine anti-murine IL-17A antibody were seen in fertility and early embryonic development and pre-and postnatal development studies in mice.
V študijah plodnosti, zgodnjega razvoja zarodka in prenatalnega ter postnatalnega razvoja pri miših niso opažali neželenih učinkov mišjega protitelesa proti mišjemu IL-17A.
No undesirable effects of canakinumab were seen following twice weekly administration to marmosets for up to 26 weeks or in an embryofoetal developmental toxicity study in pregnant marmosets.
Pri odmerjanju kanakinumaba marmozetkam dvakrat tedensko do 26 tednov in v študiji toksičnosti za razvoj zarodka oziroma ploda na brejih marmozetkah niso opažali nobenih neželenih učinkov.
No undesirable effects other than those mentioned in section 6 have been observed.
Tudi preveliki odmerki niso povzročili nobenih drugih neželenih učinkov, kot tistih, ki so navedeni v poglavju " Neželeni učinki".
No undesirable effects other than those observed and mentioned in section 4.6 “Adverse reactions” have been observed.
Tudi preveliki odmerki niso povzročili nobenih drugih neželenih učinkov, kot tistih, ki so navedeni v poglavju " Neželeni učinki".
No undesirable effects other than those observed and mentioned in the “Adverse reactions” section have been observed.
Niso zasledili nikakršnih drugačnih neželenih učinkov kot tistih, ki so navedeni v razdelku Stranski učinki.
No untoward clinical consequences were observed in clinical trials.
V kliničnih preskušanjih niso opazili neugodnih kliničnih posledic.
No virologic data at Week 48 or 144 window
V oknu 48. tedna ali 144. tedna ni viroloških podatkov
No virologic data at Week 48 or 96 window
Brez viroloških podatkov v oknu 48. ali 96. tedna
No virologic data at week 48 or week 96 window
V oknu 48. ali 96. tedna ni viroloških podatkov
No virologic data at Week 48 window
Brez viroloških podatkov v oknu 48. tedna
No virologic data at Weeks 48 window
V 48. tednu ni viroloških podatkov
No virologic data in Week 48 or
Brez viroloških podatkov v oknu
No virologic data in week 48 or 144 window
V oknu 48. ali 144. tedna ni viroloških podatkov
No virologic data in week 48 window
Brez viroloških podatkov v okviru 48. tedna
No virus analysed contained the K65R or K70E mutation.
Noben analiziran virus ni vseboval mutacije K65R ali K70E.
No vomiting§ – Overall phase
Brez bruhanja§ – celotna faza
NO, NO2 and O2 monitor calibration
Umerjanje nadzornih naprav za NO, NO2 in O2
No, you do not have to select your dose.
Ne; odmerka zdravila vam ni treba nastaviti.
No. (%) of patients with event
Št. (%) bolnikov z dogodkom
No. (%) patients requiring rescue therapiesd
Št. (%) bolnikov, ki so potrebovali rešilno terapijod
No. (%) patients with durable platelet response with stable dosee
Št. (%) bolnikov s trajnim odzivom trombocitov s stabilnim odmerkome
No. (%) patients with durable platelet responsea
Št. (%) bolnikov s trajnim odzivom trombocitova
No. (%) patients with overall platelet responseb
Št. (%) bolnikov s celotnim odzivom trombocitovb
No. at risk
893)
No. at Risk
Št. ogroženih oseb
No. at Risk:
Št. ogroženih:
No. censored
število cenzuriranih
No. of events / No. of patients
št. dogodkov/ št. bolnikov
No. of events*
število dogodkov
No. of Isolates
Št. izolatov
No. of patients at risk Time (months)
Število ogroženih bolnikov Čas (meseci)
No. of patients included in the analysis
Št. bolnikov, vključenih v analizo
No. of patients included in the analysis Responders (%)
Št. bolnikov, vključenih v analizo
No. of patients still at risk
Št. bolnikov, izpostavljenih tveganju
No. of patients still at risk Time (months)
Št bolnikov, izpostavljenih tveganju čas (meseci)
no. of patients with an event Median months
Št. bolnikov z dogodkom Mediana (meseci)
No. of severe infections
Št. hudih okužb
No. of sprays/ treatment
Št. razprškov/ zdravljenje
No. of subjects
Št. preiskovancev
No. of Subjects at Risk
Št. ogroženih preiskovancev
No. patients with event (%)
število bolnikov z dogodkom (%)
No. subjects
Št. oseb
NO16966: Avastin 7.5 mg/kg of body weight every 3 weeks in combination with oral capecitabine and intravenous oxaliplatin (XELOX) or Avastin 5 mg/kg every 2 weeks in combination with leucovorin plus 5-fluorouracil bolus, followed by 5-fluorouracil infusion, with intravenous oxaliplatin (FOLFOX-4).
NO16966: zdravilo Avastin 7,5 mg/kg telesne mase vsake 3 tedne v kombinaciji s kapecitabinom peroralno in oksaliplatinom intravensko (shema XELOX) ali zdravilo Avastin 5 mg/kg telesne mase vsaka 2 tedna v kombinaciji z levkovorinom in bolusom 5-fluorouracila, sledila je infuzija 5-fluorouracila z oksaliplatinom intravensko (shema FOLFOX-4).
Nobilis IB 4-91 given at day-old can adversely affect the efficacy of turkey rhinotracheitis (TRT) vaccine given within 7 days.
Nobilis IB 4-91, s katerim cepimo enodnevne živali, lahko zmanjša učinkovitost cepiva proti puranjemu rinotraheitisu, danega v 7 dneh.
Nobilis IB 4-91 is intended to protect chickens against respiratory signs of disease caused by IBV variant strain 4-91 only and should not be used as a replacement for other IBV vaccines.
Nobilis IB 4-91 je namenjen samo za zaščito piščancev proti respiratornim znakom bolezni, ki jo povzroča variantni sev virusa kužnega bronhitisa perutnine 4-91, in ga ne smemo uporabljati kot nadomestilo za druga cepiva, pripravljena iz virusov kužnega bronhitisa.
Nobilis IB 4-91, lyophilisate for suspension for chicken
Nobilis IB 4-91, liofilizat za suspenzijo za piščance
Nobilis IB Primo QX lyophilisate and solvent for suspension for chicken Nobilis IB Primo QX lyophilisate for suspension for chicken
Nobilis IB Primo QX, liofilizat in vehikel za suspenzijo za piščance Nobilis IB Primo QX liofilizat za suspenzijo za piščance
Nobilis IB Primo QX lyophilisate and solvent for suspension for chicken Nobilis IB Primo QX lyophilisate for suspension for chicken
Nobilis IB Primo QX, liofilizat in vehikel za suspenzijo za piščance Nobilis IB Primo QX, liofilizat za suspenzijo za piščance
Nobilis IB Primo QX lyophilisate and solvent for suspension for chickens Nobilis IB Primo QX lyophilisate for suspension for chickens
Nobilis IB Primo QX, liofilizat in vehikel za suspenzijo za piščance Nobilis IB Primo QX, liofilizat za suspenzijo za piščance
Nobilis IB Primo QX lyophilisate for suspension for chicken
Nobilis IB Primo QX, lofilizat za suspenzijo za piščance
Nobilis IB4-91 has been shown to be safe in layers and breeders during lay.
Pokazalo se je, da je uporaba cepiva Nobilis IB4-91 varna pri nesnicah in matični jati v obdobju nesnosti.
Nobilis IB4-91 has been shown to be safe in layers and breeders during lay.
Pokazalo se je, da je uporaba Nobilisa IB4-91 varna pri nesnicah in matični jati v obdobju nesnosti.
Nobilis IB4-91, lyophilisate for suspension for chicken
Nobilis IB 4-91, liofilizat za suspenzijo za piščance
Nobilis Influenza H5N2 emulsion for injection
Nobilis Influenza H5N2 emulzija za injiciranje
Nobilis Influenza H5N2 emulsion for injection for chickens.
Nobilis Influenza H5N2, emulzija za injiciranje za piščance.
Nobilis Influenza H5N2 emulsion of injection for chickens.
Nobilis Influenza H5N2 emulzija za injiciranje za piščance.
Nobilis Influenza H5N6 Emulsion for injection
Nobilis Influenza H5N6 Emulzija za injiciranje
Nobilis Influenza H5N6 emulsion for injection for chickens
Nobilis Influenza H5N6, emulzija za injiciranje za piščance
Nobilis Influenza H7N1 Emulsion for injection
Nobilis Influenza H7N1 Emulzija za injiciranje
Nobilis Influenza H7N1 emulsion for injection
Nobilis Influenza H7N1, emulzija za injiciranje
Nobilis Influenza H7N1 Emulsion of injection
Nobilis Influenza H7N1 Emulzija za injiciranje
Nobilis OR
Nobilis OR inac
Nobilis OR Inac is used to vaccinate female chickens that are being used for breeding broilers (chickens bred for meat) against the bacterium O. rhinotracheale serotype A. This immunity is then passed on to the chickens’ offspring, so that the broilers are protected against infection with the same type of bacteria.
Zdravilo Nobilis OR Inac se uporablja za cepljenje piščancev ženskega spola, ki se uporabljajo za vzrejo brojlerjev (piščancev, ki se redijo za meso) proti bakteriji O. rhinotracheale, serotipa A. Ta imunost se nato prenese na potomce cepljenih piščancev (kokoši), tako da so brojlerji zaščiteni pred okužbo z enako vrsto bakterije.
Nobivac Bb lyophilisate and solvent for suspension for cats
Nobivac Bb liofilizat in vehikel za suspenzijo za mačke
Nobivac L4 suspension for injection for dogs
Nobivac L4 suspenzija za injiciranje za pse
Nobivac L4 suspension for injection for dogs
Nobivac L4, suspenzija za injiciranje za pse
Nobivac L4, suspension for injection for dogs
Nobivac L4, suspenzija za injiciranje za pse
Nobivac Myxo-RHD lyophilisate and solvent for suspension for injection for rabbits
Nobivac Myxo-RHD liofilizat in vehikel za suspenzijo za injiciranje za kunce
Nobivac Myxo-RHD Solvent
Nobivac Myxo-RHD vehikel
Nobivac Myxo-RHD, like all vaccines, works by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease.
Zdravilo Nobivac Myxo-RHD podobno kot vsa cepiva deluje tako, da imunski sistem (naravni obrambni mehanizem telesa) „nauči“, kako naj se brani pred boleznijo.
Nobivac Piro contains small amounts of antigens (soluble parasite antigens) from B. canis and the related species B. rossi that have been extracted from cultures of the parasites in red blood cells.
Zdravilo Nobivac Piro vsebuje majhne količine antigenov (topnih parazitskih antigenov) zajedavca B. canis in sorodne vrste B. rossi, pridobljenih iz kultur parazitov v rdečih krvnih celicah.
Nobivac Piro lyophilisate and solvent for suspension for injection for dogs
Nobivac Piro, liofilizat in vehikel za suspenzijo za injiciranje za pse
Nobivac Piro lyophilisate and solvent for suspension for injections for dogs
Nobivac Piro, liofilizat in vehikel za suspenzijo za injiciranje za pse
Nocturia
nikturija
Nocturia Pollakiuria Urine odour abnormal
motnje menstruacije
Nocturia Polyuria Urine flow decreased
labši curek urina
Nocturia** Renal impairment**,b
disurija poliurija*,f
Nocturia** Renal impairment**,b
nikturija** okvara ledvic**,b
Nocturia, dysuria
nikturija, disurija,
Nocturia, renal impairmentF
nikturija, okvara ledvicF
Nocturia, urinary tract infection
nikturija, okužba sečil
Nocturnal confirmed 3
Potrjene nočne3
Nocturnal confirmed hypoglycaemia was defined as episodes between midnight and 6 a.m. b Episodes from week 16.
Potrjena nočna hipoglikemija je bila opredeljena kot hipoglikemija med polnočjo in 6. uro zjutraj. b Pojavi od 16. tedna
nodes
0,0020
nodes
bezgavk
Nodules and cysts
vozliči in ciste
Nodules are to be pre-treated at a light doses of 50 J/cm of diffuser length with a short (< 2.5 cm) fibre optic diffuser placed directly against the nodules followed by standard balloon application as described above.
50 J/cm dolžine difuzorja z difuzorjem s kratkimi (< 2,5 cm) optičnimi vlakni, nameščenim neposredno na vozličih, čemur sledi standardna uporaba balona, kot je opisano zgoraj.
Noise in the ear such as buzzing, ringing or whistling
hrup v ušesih, kot so brenčanje, zvonenje ali piskanje
Nomegestrol acetate is excreted via urine and feces.
Nomegestrolacetat se izloča prek urina in blata.
Nomegestrol acetate, the progestogen in IOA, is derived from the hormone progesterone.
Nomegestrolacetat, to je progestogen v zdravilu IOA, nastane iz hormona progesterona.
Nomegestrol acetate, the progestogen in Zoely, is derived from the hormone progesterone.
Nomegestrolacetat, to je progestogen v zdravilu Zoely, nastane iz hormona progesterona.
Nominal Change in Recurrenc e Rate vs Previous Year (%)
Nominalna sprememb a deleža ponovitve v primerjavi s prejšnjim letom (%)
Nominal P value (log rank)
Nominalna p-vrednost (test log-rank)a
Nominal p- value
Nominalna vrednost p
Non cardiac chest pain
nekardiogena bolečina v prsnem košu
Non compliance with fasting requirements tended to be a feature of those cases.
Ti primeri niso povezani s postenjem.
Non depolarising muscle relaxant acting medicinal products
Zdravila, ki delujejo kot nedepolarizirajoči mišični relaksanti
Non high-density lipoprotein cholesterol (Non-HDL-C) (mg/dL)
Lipoproteinski holesterol nevelike gostote (non- HDL-C) (mg/dl)
Non Interventional PASS: In order to investigate the safety and effectiveness in real clinical practice as well as long-term safety and effectiveness in all patients treated with Zalmoxis, the MAH should conduct and submit the results of study TK011 using the EBMT registry including all patients treated with Zalmoxis.
Neintervencijska študija o varnosti zdravila po pridobitvi dovoljenja za promet z zdravilom (PASS): Za preučitev varnosti in učinkovitosti med dejansko klinično uporabo, kot tudi dolgotrajne varnosti in učinkovitosti pri vseh bolnikih, zdravljenih z zdravilom Zalmoxis, mora imetnik dovoljenja za promet z zdravilom s pomočjo registra EBMT izvesti študijo TK011, v katero bo vključil vse bolnike, zdravljene z zdravilom Zalmoxis, in predložiti njene rezultate.
Non species related breakpoints: S ≤ 0.5 mg/L and R > 1 mg/L (NB: Susceptibility of staphylococci to ertapenem is inferred from the methicillin susceptibility)
Referenčne vrednosti ne glede na vrsto: S ≤ 0,5 mg/l in R > 1 mg/l (Občutljivost stafilokokov na ertapenem se sklepa na osnovi občutljivosti na meticilin.)
Non species related S  1 mg/l and R > 4 mg/l
Neodvisne od vrste S  1 mg/l in R > 4 mg/l
Non steroidal anti-inflammatory drugs (NSAIDS) have been reported to blunt the antihypertensive effect of beta-blocking agents.
Za nesteroidna protivnetna zdravila (NSAIDs) so poročali, da izničijo antihipertenzivni učinek antagonistov adrenergičnih receptorjev beta.
Non- clinical studies demonstrated that Teysuno did not appear to affect male or female fertility in the rat (see section 5.3).
Neklinične študije so pokazale, da zdravilo Teysuno ni vplivalo na plodnost samcev ali samic pri podganah (glejte poglavje 5.3).
Non- HDL-C (%)
ne- HDL- H (%)
Non- HDL-C (%)
ne- HDL-H (%)
Non- inferiority criteria were met if the lower bound of the 97.5% confidence interval for the difference in Complete Response rates of intravenous palonosetron minus intravenous ondansetron was larger than -15%.
Kriteriji ne-manjvrednosti so bili izpolnjeni, če je bila spodnja meja 97,5-odstotnega intervala za razliko med pogostnostjo popolnega odziva pri intravenskem palonosetronu in pri intravenskem ondansetronu večja kot -15 %.
Non- PVC containing administration sets, such as those which are polyethylene-lined, should be used.
Uporabljati je potrebno komplete za aplikacijo, ki ne vsebujejo PVC in so npr. izdelani iz polietilena.
Non- serious epistaxis was the most frequent bleeding event.
Najpogostejša krvavitev je bila epistaksa, ki ni bila resna.
Non-24- hour sleep-wake disorder is a condition that occurs almost exclusively in people who are completely blind, where patients have sleep patterns that are not synchronised with day and night and often follow a cycle that is longer than the standard 24-hour clock.
Ne-24-urni cikel spanja in budnosti je motnja, ki se pojavlja skoraj izključno pri popolnoma slepih osebah in pri kateri imajo bolniki vzorce spanja, ki niso usklajeni z dnevom in nočjo ter pogosto sledijo ciklu, daljšemu od standardnega 24-urnega dneva.
Non-albicans species ¶: all
Drugi sevi (ne albicans) ¶ skupaj
Non-ambulatory
Imobilni bolniki
Non-apheresis (N = 65)
Brez afereze (N = 65)
Non-arteritic
bolezni
Non-arteritic
nearteritična anteriorna
Non-arteritic anterior
nearteritična anteriorna
Non-arteritic anterior
zaznavanja
Non-arteritic anterior ischaemic optic
nearteritična anteriorna ishemična
Non-arteritic anterior ischaemic optic neuropathy (NAION) and sudden loss of hearing have been reported in a small number of postmarketing and clinical trial cases with other PDE5 inhibitors.
V obdobju po trženju zdravila in med kliničnimi študijami uporabe drugih zaviralcev PDE5 so poročali o majhnem številu primerov nearteritične anteriorne ishemične optične nevropatije (NAION) in nenadne izgube sluha.
Non-arteritic anterior ischaemic optic neuropathy (NAION)*,
nearteritična anteriorna ishemična optična nevropatija (NAION),
Non-arteritic anterior ischemic optic neuropathy Visual defects
nearteritična anteriorna ishemična optična nevropatija motnje vida
Non-Asians 1143 6.2% vs 7.3%
6,6 % v prim. z 9,8
Non-autografted mixed wounds
Mešane rane brez avtotransplantata
Non-Black
Ne-črnci
Non-bleeding adverse reactions in Table 1 are summarized for both the TRA 2°P TIMI 50 and TRACER studies. (See Table 1.)
Neželeni učinki, ki niso krvavitve, v preglednici 1 so povzeti za obe študiji, TRA 2°P TIMI 50 in TRACER. (Glejte preglednico 1.)
Non-CABG PLATO Major
PLATO hude, nepovezane s CABG
Non-CABG related bleeding and non-procedural related bleeding: Ticagrelor and clopidogrel did not differ in non-CABG PLATO-defined Major Fatal/Life-threatening bleeding, but PLATO- defined Total Major, TIMI Major, and TIMI Major + Minor bleeding were more common with ticagrelor.
Krvavitve, nepovezane z obvodno operacijo koronarnih arterij in nepovezane s postopki: Ticagrelor in klopidogrel se nista razlikovala po hudih krvavitvah s smrtnim izidom/smrtno nevarnih krvavitvah (po opredelitvi PLATO), nepovezanih s CABG, toda vse hude po opredelitvi PLATO, hude po TIMI ter hude + blage po TIMI pa so bile s ticagrelorjem pogostejše.
Non-CABG TIMI major bleeding event
Velika krvavitev, ki ni povezana s CABG TIMI
Non-CABG-related TIMI major or minor bleeding rates:
Stopnje večjih in manjših krvavitev po TIMI, nepovezanih s CABG:
Non-cancerous (benign) tumours in your breast or liver
ne-rakavi (benigni) tumorji dojke ali jeter
Non-cardiac chest pain
bolečina v prsih, ki ne izvira od srca
Non-cardiac chest pain
nekardialna bolečina v prsnem košu
Non-cardiac chest pain Asthenia
nekardialna bolečina v prsih
Non-cardiac chest pain, impaired wound healing
nekardialna bolečina v prsnem košu, slabo celjenje ran
non-cardiogenic
pnevmonitis,
Non-Cardiovascular Medicinal Products
Zdravila, ki niso kardiovaskularna
Non-Caucasian patients
Bolnice, ki niso belke
Non-CF Bronchiectasis
Bronhiektazija, ki ni posledica cistične fibroze (CF)
Non-Cirrhotic (n=197)
Brez ciroze (n = 197)
non-cirrhotic and cirrhotic
Brez ciroze in s cirozo
Non-cirrhotic§
Brez ciroze §
Non-Clade B
Virusni podtipi, razen B
Non-Clade B
Virusni podtipi, razen klad B